Clinical Trials Browser

Carcinoma, Ovarian Epithelial × pembrolizumab × 30 days × Clear all

NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Turcot syndrome, Carcinoma, Ovarian Epithelial